These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9592567)

  • 1. In vitro antifungal activity of CAN-296: a naturally occurring complex carbohydrate.
    Ben-Josef AM; Manavathu EK; Platt D; Sobel JD
    J Antibiot (Tokyo); 1997 Nov; 50(11):937-43. PubMed ID: 9592567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
    Martín E; Parras P; Lozano MC
    Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton translocating ATPase mediated fungicidal activity of a novel complex carbohydrate: CAN-296.
    Ben-Josef AM; Manavathu EK; Platt D; Sobel JD
    Int J Antimicrob Agents; 2000 Feb; 13(4):287-95. PubMed ID: 10755243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
    Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antifungal susceptibility testing of Candida blood isolates and evaluation of the E-test method.
    Lu JJ; Lee SY; Chiueh TS
    J Microbiol Immunol Infect; 2004 Dec; 37(6):335-42. PubMed ID: 15599465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test].
    Park JY; Shin JH; Uh Y; Kim EC; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
    Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides.
    Helmerhorst EJ; Reijnders IM; van't Hof W; Simoons-Smit I; Veerman EC; Amerongen AV
    Antimicrob Agents Chemother; 1999 Mar; 43(3):702-4. PubMed ID: 10049295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative sensitivity of yeasts to antifungal agents using a standardized micromethod].
    Guinet R
    Pathol Biol (Paris); 1986 May; 34(5):536-9. PubMed ID: 3534739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
    Morace G; Manzara S; Dettori G
    Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts.
    Gadea I; Cuenca M; Gegúndez MI; Zapardiel J; Valero ML; Soriano F
    J Antimicrob Chemother; 1997 Apr; 39(4):453-9. PubMed ID: 9145817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
    Pfaller MA; Messer SA; Jones RN; Castanheira M
    J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
    Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
    J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fungal infection of cystic fibrosis patients - single center experience.
    Garczewska B; Jarzynka S; Kuś J; Skorupa W; Augustynowicz-Kopeć E
    Pneumonol Alergol Pol; 2016; 84(3):151-9. PubMed ID: 27238177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant
    Locke JB; Almaguer AL; Donatelli JL; Bartizal KF
    Infect Dis Obstet Gynecol; 2018; 2018():7040498. PubMed ID: 29681727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.